← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biostrategies, Lc
State University, AR
$16,070,966
Total funding
17
Grants
Funding over time
peak $2.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,070,966 · 17
By mechanism
R44$12,861,758 · 6
R43$3,209,208 · 11
Investigators at Biostrategies, Lc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)$1,500,000
R44 · FY2023 · NS
Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme$1,500,000
R44 · FY2025 · NS
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)$1,498,067
R44 · FY2024 · NS
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,366,586
R44 · FY2017 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,237,037
R44 · FY2017 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,147,007
R44 · FY2018 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$1,144,737
R44 · FY2020 · HD
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,071,897
R44 · FY2018 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$905,262
R44 · FY2021 · HD
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$831,740
R44 · FY2015 · NS
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$659,425
R44 · FY2016 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$458,316
R43 · FY2014 · NS
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS$390,497
R43 · FY2022 · NS
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases$295,923
R43 · FY2023 · HD
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease$293,232
R43 · FY2019 · HL
Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease$285,783
R43 · FY2013 · NS
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery$250,000
R43 · FY2020 · AR
Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease$225,000
R43 · FY2014 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$225,000
R43 · FY2016 · HD
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme$225,000
R43 · FY2018 · AR